Cargando…

Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report

BACKGROUND: Few reports exist of the long-term management of recurrent and progressive papillary thyroid carcinoma (PTC) with a tyrosine kinase inhibitor for over 5 years. CASE PRESENTATION: A 57-year-old woman was referred to a psychiatric hospital for the treatment of schizophrenia. The patient ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Tsuneo, Kobayashi, Hironobu, Senaha, Tetsu, Imaizumi, Toshiaki, Murata, Yoshiharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795247/ https://www.ncbi.nlm.nih.gov/pubmed/35084585 http://dx.doi.org/10.1186/s40792-022-01374-0

Ejemplares similares

A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
por: Iwasaki, Hiroyuki, et al.
Publicado: (2020)

Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report
por: Tori, Masayuki, et al.
Publicado: (2018)

Anaplastic thyroid carcinoma diagnosed after treatment of lenvatinib for papillary thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma
por: Takinami, Masaki, et al.
Publicado: (2020)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
por: Nakamura, Hajime, et al.
Publicado: (2020)

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient
por: Morelli, S., et al.
Publicado: (2017)

Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib
por: Tang, Ping, et al.
Publicado: (2022)

Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients
por: Masaki, Chie, et al.
Publicado: (2021)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

Annual Hazard Rate of Recurrence in Middle Eastern Papillary Thyroid Cancer over a Long-Term Follow-Up
por: Siraj, Abdul K., et al.
Publicado: (2020)

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma
por: Groden, Phillip J., et al.
Publicado: (2018)

Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report
por: Tsuboi, Mitsuhiro, et al.
Publicado: (2017)

Recurrence Factors and Characteristic Trends of Papillary Thyroid Cancer over Three Decades
por: Chatchomchuan, Waralee, et al.
Publicado: (2021)

MON-453 Dramatic Clinical Response to Lenvatinib in a Pediatric Patient with Advanced Metastatic Papillary Thyroid Carcinoma
por: Dujovne, Noelia Vanesa, et al.
Publicado: (2020)

Large papillary thyroid cancer bed recurrence causing overlying skin ulceration and bleeding
por: Boulas, Konstantinos A., et al.
Publicado: (2022)

Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer
por: Yamazaki, Haruhiko, et al.
Publicado: (2019)

Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
por: Buenaventura, Daisy Carolina, et al.
Publicado: (2023)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
por: Tateai, Yoshikazu, et al.
Publicado: (2023)

Anaplastic thyroid cancer with long-term survival with lenvatinib therapy and preservation of laryngeal function after one-stage reconstruction: A case report
por: Tanaka, Akihisa, et al.
Publicado: (2021)

Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021)

Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib
por: Jin, Meihua, et al.
Publicado: (2023)

Prognostic parameters for recurrence of papillary thyroid microcarcinoma
por: Kim, Tae Yong, et al.
Publicado: (2008)

Clinicopathological features of recurrent papillary thyroid cancer
por: Zhu, Jian, et al.
Publicado: (2015)

Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
por: Woo, Joohyun, et al.
Publicado: (2021)

Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report
por: Miwa, Takao, et al.
Publicado: (2021)

A rare case of the recurrent surgery for cribriform-morular variant of papillary thyroid carcinoma
por: Enomoto, Keisuke, et al.
Publicado: (2019)

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
por: Robinson, Bruce, et al.
Publicado: (2016)

Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan
por: Sugitani, Iwao, et al.
Publicado: (2019)

Multiple Metastases of Parathyroid and Papillary Thyroid Carcinoma in a Female Patient Treated with Long-Term Hemodialysis
por: Krupinova, Julia, et al.
Publicado: (2023)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
por: Roque, João, et al.
Publicado: (2023)

Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence
por: de Castro, Taciana Padilha, et al.
Publicado: (2019)

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program
por: Balmelli, Catharina, et al.
Publicado: (2018)

A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report
por: Todoroki, Takeshi, et al.
Publicado: (2006)

Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report
por: Yokoo, Hideki, et al.
Publicado: (2020)

Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents
por: Huang, Dongmei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jggbsvjg086ecnfunti523nlpq